View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 22, 2021

Lilly signs deal to supply Covid-19 antibody combo to European countries

On obtaining approval in Europe, participating nations in the EU and EEA can buy the antibodies directly from Lilly.

Eli Lilly and Company has entered a joint procurement agreement with the European Commission (EC) to deliver up to 220,000 doses of antibodies bamlanivimab and etesevimab to treat confirmed Covid-19 patients.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The bamlanivimab and etesevimab combination therapy is intended for the treatment of Covid-19 patients aged 12 years and above who do not need supplemental oxygen and are at high risk of progressing to severe disease.

Bamlanivimab is a recombinant, neutralising human IgG1 monoclonal antibody directed against the SARS-CoV-2 spike protein.

A recombinant fully human monoclonal neutralising antibody, etesevimab specifically attaches to the SARS-CoV-2 surface spike protein receptor-binding domain.

The latest deal will aid in offering access to therapies by facilitating participating countries in the EU and European Economic Area (EEA) to procure the products directly from Lilly, on obtaining approval for emergency use or marketing authorisation at the EU level.

Lilly noted that the quantities acquired may differ based on local requirements as decided by participating countries.

In March, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly bamlanivimab administered alone and with etesevimab for treating Covid-19 in patients aged 12 and older.

The CHMP scientific opinion supports national decision-making within EU member states on the use of treatments before a formal marketing authorization is granted, during a public health emergency.

Lilly International senior vice-president and president Alfonso Zulueta said: “Bamlanivimab and etesevimab have played an important role in the fight against Covid-19, helping hundreds of thousands of patients globally.

“Lilly is pleased to have reached this agreement with the European Commission which opens the door for many European countries to access this life-saving treatment option for patients with Covid-19.”

According to the preclinical data, bamlanivimab plus etesevimab showed to retain neutralisation activity against variants of SARS-CoV-2 presently in circulation in several countries, including Delta and Alpha variants.

The US Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for Eli Lilly’s bamlanivimab plus etesevimab last week, to include post-exposure prophylaxis in some people to prevent Covid-19.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU